Skip to search formSkip to main contentSkip to account menu

dabigatran etexilate 150 MG Oral Capsule [Pradaxa]

Known as: DABIGATRAN ETEXILATE MESYLATE 150 mg ORAL CAPSULE [Pradaxa], Pradaxa 150 MG (as dabigatran etexilate mesylate 172.95 MG) Oral Capsule, Pradaxa 150 MG Oral Capsule 
National Institutes of Health

Related topics

Related topics

24 relations
1-ButanolAcacia substanceCarrageenanEthanol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation
Dabigatran etexilate (Pradaxa®) is approved in the EU for the prevention of stroke and systemic embolism in patients with… 
Review
2015
Review
2015
Idarucizumab: First Global Approval
Idarucizumab (Praxbind®) is a fully humanized, monoclonal antibody fragment developed by Boehringer Ingelheim as a specific… 
Review
2014
Review
2014
Dabigatran Etexilate: A Review of Its Use in the Treatment of Acute Venous Thromboembolism and Prevention of Venous Thromboembolism Recurrence
Dabigatran etexilate (Pradaxa®, Prazaxa®) has recently been approved for the treatment of acute venous thromboembolism (VTE) and… 
Review
2013
Review
2013
Use of New Oral Anticoagulants in Antiphospholipid Syndrome
The current mainstay of treatment of thrombotic APS is long-term anticoagulation with oral vitamin K antagonists (VKA) such as… 
Highly Cited
2013
Highly Cited
2013
Prise en charge des complications hémorragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d’intérêt en H…
Review
2012
Review
2012
Dabigatran Etexilate
Dabigatran etexilate (Pradaxa®, Pradax™, Prazaxa®) is indicated for the primary prevention of venous thromboembolic (VTE) events… 
Highly Cited
2012
Highly Cited
2012
A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting
AbstractBackground: It has been estimated that major orthopaedic surgery has the highest risk of venous thromboembolism (deep… 
2012
2012
Positive Outcome After Intentional Overdose of Dabigatran
Dabigatran (Pradaxa™), an orally active direct thrombin inhibitor, was approved by the United States Food and Drug Administration… 
2012
2012
Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency
Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency - 
Review
2009
Review
2009
Newer anticoagulants in 2009
Several newer anticoagulants are under clinical development. Recently two of them, Dabigatran etexilate/Pradaxa®. and Rivaroxaban… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)